NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
611 trialsNCT01590069 2026-04-16
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03435952 2026-04-16
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT04897321 2026-04-15
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06049576 2026-04-15
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06044857 2026-04-14
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT06303713 2026-04-08
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT07054307 2026-04-07
MH-Penile-001
West China Hospital
Phase 1 Recruiting
NCT04715191 2026-04-06
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Recruiting
NCT04147806 2026-04-03
PROSINT
Albert Einstein College of Medicine
Phase 1 Active not recruiting
NCT05839119 2026-04-02
TASUC-Neo
Brown University
Phase 1 Terminated
NCT07140315 2026-04-02
DK222 Study at Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT07401875 2026-04-02
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06253845 2026-04-01
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT07054346 2026-04-01
LUTACT
University of California, San Francisco
Phase 1 Recruiting
NCT03674814 2026-03-31
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Completed
NCT04886986 2026-03-31
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT06193486 2026-03-31
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT05398302 2026-03-30
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04167969 2026-03-27
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07495293 2026-03-27
Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer
Yonsei University
Phase 1 Not yet recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05700461 2026-03-20
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Phase 1 Enrolling by invitation
NCT04007744 2026-03-18
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Active not recruiting
NCT05055050 2026-03-18
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05245006 2026-03-17
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
University of California, San Francisco
Phase 1 Active not recruiting
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT04004442 2026-03-13
COAXIN
University of Oklahoma
Phase 1 Active not recruiting
NCT05833867 2026-03-13
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT05843448 2026-03-13
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
University of California, Davis
Phase 1 Recruiting
NCT06173349 2026-03-13
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
Phase 1 Recruiting
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT06369246 2026-03-09
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06963346 2026-03-09
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Suspended
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01104350 2026-03-05
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT05122546 2026-03-05
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05806814 2026-03-05
OU-SCC-EXCITE
University of Oklahoma
Phase 1 Recruiting
NCT06826768 2026-03-04
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT04473781 2026-03-02
Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT04610671 2026-02-27
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07128680 2026-02-27
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
Phase 1 Recruiting